{"id":2263,"date":"2017-08-17T16:54:49","date_gmt":"2017-08-17T11:24:49","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=2263"},"modified":"2021-07-24T12:56:49","modified_gmt":"2021-07-24T07:26:49","slug":"business-cocktail-11","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-11","title":{"rendered":"Business CockTail"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69fc4fe7c2f42\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69fc4fe7c2f42\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/business-cocktail-11\/#GlaxoSmithKline_taps_Baltimores_Insilico_for_AI-based_drug_discovery\" >GlaxoSmithKline taps Baltimore\u2019s Insilico for AI-based drug discovery<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/business-cocktail-11\/#VentureMed_nets_15M_for_PAD_catheter\" >VentureMed nets $15M for PAD catheter<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/business-cocktail-11\/#Zai_Lab_files_for_115M_Nasdaq_IPO_to_take_Tesaro_Bristol-Myers_cancer_drugs_through_late-phase_trials\" >Zai Lab files for $115M Nasdaq IPO to take Tesaro, Bristol-Myers cancer drugs through late-phase trials<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/business-cocktail-11\/#James_Mullen_backs_Vicarius_22M_series_A_to_equip_ex-Biogen\" >James Mullen backs Vicarius\u2019 $22M series A to equip ex-Biogen<\/a><\/li><\/ul><\/nav><\/div>\n<h3 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"GlaxoSmithKline_taps_Baltimores_Insilico_for_AI-based_drug_discovery\"><\/span>GlaxoSmithKline taps Baltimore\u2019s Insilico for AI-based drug discovery<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p style=\"text-align: justify;\">GlaxoSmithKline and Insilico Medicine are partnering to explore how the latter\u2019s artificial intelligence technology can aid in the drug discovery process. The duo kept mum on the details but said the agreement comes after Baltimore-based Insilico completed a series of pilot challenges. First, Glaxo will evaluate Insilico\u2019s technology in the identification of novel biological targets and pathways of interest. Based at Johns Hopkins University\u2019s Emerging Technology Centers, Insilico uses genomics, big data analysis and deep learning for in silico drug discovery, or drug discovery through computer modeling. The company has its own drug discovery programs in cancer, amyotrophic lateral sclerosis, and diabetes, as well as in age-related diseases such as sarcopenia, Parkinson\u2019s disease, and Alzheimer\u2019s disease.<\/p>\n<h3 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"VentureMed_nets_15M_for_PAD_catheter\"><\/span>VentureMed nets $15M for PAD catheter<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p style=\"text-align: justify;\">VentureMed Group, which markets a catheter used in the treatment of peripheral artery disease, raised $15 million in a series B round. The funds will support ongoing and future clinical trials, as well as the company\u2019s regulatory and reimbursement efforts for the device. The new funding will also bankroll VentureMed\u2019s R&amp;D programs and boost its global sales team. The Toledo, Ohio-based company\u2019s Flex Scoring Catheters are used to prepare femoral popliteal arteries for PAD treatments, including the insertion of a drug-coated balloon, bare metal stents or drug-eluting stents. The device is CE marked and FDA-cleared. New investor Endeavour Vision led the round, and RiverVest Venture Partners, another new backer, also participated.<\/p>\n<h3 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"Zai_Lab_files_for_115M_Nasdaq_IPO_to_take_Tesaro_Bristol-Myers_cancer_drugs_through_late-phase_trials\"><\/span>Zai Lab files for $115M Nasdaq IPO to take Tesaro, Bristol-Myers cancer drugs through late-phase trials<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p style=\"text-align: justify;\">Zai Lab has filed to raise up to $115 million in a Nasdaq IPO. The biotech plans to use the money to hustle cancer drugs licensed from Bristol-Myers Squibb and Tesaro through late-phase trials in its home country of China. Since setting up shop in 2014, Zai Lab has quickly established a clinical-phase pipeline by striking deals for assets with GlaxoSmithKline, Sanofi, UCB, Bristol-Myers, Paratek Pharmaceuticals, and Tesaro. The drugs Zai Lab picked up from the latter three companies are among the most advanced in its pipeline\u2014and are the focus of the planned post-IPO spending spree. Phase 3 trials of niraparib, the Tesaro PARP inhibitor the FDA approved earlier this year, in cancer of the ovaries, breasts, and lung will account for a sizable, as-yet-undisclosed slice of the IPO haul. The plan is to start a phase 3 ovarian cancer trial as a second-line maintenance therapy later this year, before moving into a first-line study in the first half of next year. Zai Lab is also aiming to kick off a phase 3 trial in gBRCA-positive breast cancer patients by the midpoint of next year.<\/p>\n<h3 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"James_Mullen_backs_Vicarius_22M_series_A_to_equip_ex-Biogen\"><\/span>James Mullen backs Vicarius\u2019 $22M series A to equip ex-Biogen<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p style=\"text-align: justify;\">James Mullen has teamed up with colleagues from his days leading Biogen to help U.S. biotechs bring drugs to market in Europe. The resulting startup has raised CHF 21 million ($22 million) to get off the ground\u2014and plans to return for about 10 times that once its business gets up to speed. Vicarius Pharma will use the series A money (PDF) to begin building a business it sees providing biotechs with a better option for commercializing drugs in Europe. Led by ex-Biogen and Elan COO Hans Peter Hasler, Vicarius will use its own money to build European commercial subsidiaries for U.S. biotechs to manage everything from regulatory strategies to post-launch activities. After a certain point, the biotechs will take over the running of their subsidiaries.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>GlaxoSmithKline taps Baltimore\u2019s Insilico for AI-based drug discovery GlaxoSmithKline and Insilico Medicine are partnering to explore how the latter\u2019s artificial intelligence technology can aid in the drug discovery process. The duo kept mum on the details but said the agreement comes after Baltimore-based Insilico completed a series of pilot challenges. First, Glaxo will evaluate Insilico\u2019s [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":1200,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[129,137,988,985,17560,561,986,989,987],"industry":[17225],"therapeutic_areas":[17240,17245,17228],"class_list":["post-2263","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-bristol-myers","tag-cancer","tag-cancer-drugs","tag-glaxosmithkline","tag-peripheral-artery-disease","tag-tesaro","tag-vicarius","tag-vicarius-pharma","tag-zai-lab","industry-pharmaceutical","therapeutic_areas-endocrinology-and-metabolic-disorders","therapeutic_areas-neurology","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>GlaxoSmithKline, VentureMed, Zai LabBusiness CockTail<\/title>\n<meta name=\"description\" content=\"GlaxoSmithKline and Insilico Medicine are partnering to explore how the latter\u2019s artificial intelligence technology can aid in the drug discovery process.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/business-cocktail-11\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GlaxoSmithKline, VentureMed, Zai LabBusiness CockTail\" \/>\n<meta property=\"og:description\" content=\"GlaxoSmithKline and Insilico Medicine are partnering to explore how the latter\u2019s artificial intelligence technology can aid in the drug discovery process.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/business-cocktail-11\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2017-08-17T11:24:49+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:26:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/09\/15170357\/14130776__original.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1\" \/>\n\t<meta property=\"og:image:height\" content=\"1\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"GlaxoSmithKline, VentureMed, Zai LabBusiness CockTail","description":"GlaxoSmithKline and Insilico Medicine are partnering to explore how the latter\u2019s artificial intelligence technology can aid in the drug discovery process.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-11","og_locale":"en_US","og_type":"article","og_title":"GlaxoSmithKline, VentureMed, Zai LabBusiness CockTail","og_description":"GlaxoSmithKline and Insilico Medicine are partnering to explore how the latter\u2019s artificial intelligence technology can aid in the drug discovery process.","og_url":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-11","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2017-08-17T11:24:49+00:00","article_modified_time":"2021-07-24T07:26:49+00:00","og_image":[{"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/09\/15170357\/14130776__original.jpg","width":1,"height":1,"type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-11","url":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-11","name":"GlaxoSmithKline, VentureMed, Zai LabBusiness CockTail","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-11#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-11#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/09\/15170357\/14130776__original.jpg","datePublished":"2017-08-17T11:24:49+00:00","dateModified":"2021-07-24T07:26:49+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"GlaxoSmithKline and Insilico Medicine are partnering to explore how the latter\u2019s artificial intelligence technology can aid in the drug discovery process.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/business-cocktail-11"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-11#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/09\/15170357\/14130776__original.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/09\/15170357\/14130776__original.jpg","caption":"Blue globes from drug capsule"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/09\/15170357\/14130776__original.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Bristol-Myers<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">cancer drugs<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">GlaxoSmithKline<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Peripheral Artery Disease<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Tesaro<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Vicarius<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Vicarius Pharma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Zai Lab<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Bristol-Myers<\/span>","<span class=\"advgb-post-tax-term\">Cancer<\/span>","<span class=\"advgb-post-tax-term\">cancer drugs<\/span>","<span class=\"advgb-post-tax-term\">GlaxoSmithKline<\/span>","<span class=\"advgb-post-tax-term\">Peripheral Artery Disease<\/span>","<span class=\"advgb-post-tax-term\">Tesaro<\/span>","<span class=\"advgb-post-tax-term\">Vicarius<\/span>","<span class=\"advgb-post-tax-term\">Vicarius Pharma<\/span>","<span class=\"advgb-post-tax-term\">Zai Lab<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 9 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Aug 17, 2017","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Aug 17, 2017 4:54 pm","modified":"Updated on Jul 24, 2021 12:56 pm"},"featured_img_caption":"Blue globes from drug capsule","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2263","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=2263"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2263\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/1200"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=2263"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=2263"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=2263"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=2263"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=2263"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}